Rheumatology

Understanding Your EGPA Diagnosis

At a Glance

Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare vasculitis that often begins with severe asthma and nasal polyps before progressing to blood vessel inflammation. While diagnosis is often delayed, modern treatments offer an excellent long-term prognosis and a normal lifespan.

If you are reading this, you may have spent years feeling like your health was a puzzle with missing pieces. Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly called Churg-Strauss Syndrome, is a rare type of vasculitis—a condition where the immune system causes inflammation in the blood vessels ^[1]^[2].

Because it is so rare, affecting roughly 10 to 15 people per million in various populations, many patients face a long “diagnostic odyssey” ^[3]^[4]. You might have been treated for “just” severe asthma or sinus polyps for a decade or more before the full picture of EGPA became clear ^[5]^[6]. While a diagnosis of a rare systemic disease is heavy news, there is reason for confidence: with modern treatments, the long-term outlook for EGPA is excellent, and patients can expect to live long, full lives ^[7].

The Three Phases of EGPA

Doctors often describe EGPA as progressing through three clinical phases. These phases do not always happen in a straight line, and many patients experience overlapping symptoms from different stages at the same time ^[8]^[9].

The Allergic (Prodromal) Phase: This is often the longest phase, characterized by adult-onset asthma that is difficult to control and chronic sinusitis often accompanied by nasal polyps ^[5]^[10].
The Eosinophilic Phase: In this stage, the body begins producing too many eosinophils—a type of white blood cell. These cells can build up in various tissues, causing inflammation and damage ^[11]^[10].
The Vasculitic Phase: This is the most serious stage, where blood vessels themselves become inflamed (vasculitis). Common signs include mononeuritis multiplex (severe nerve numbness or pain) and skin rashes ^[12]^[13].

Why Your Diagnosis Took So Long

It is common for patients to feel frustrated by the delay in their diagnosis. Because early symptoms like asthma and sinus issues are so common in the general population, EGPA is rarely the first suspicion ^[14]. Once symptoms of blood vessel inflammation appear, doctors use specialized lab tests and biopsies to confirm the diagnosis and ensure it isn’t just severe asthma ^[1]^[15].

Understanding Your Prognosis

While EGPA is a chronic condition that requires long-term management, the long-term survival rates are extremely high, with the vast majority of patients living decades past diagnosis ^[7].

A critical part of your early care will involve checking for cardiac involvement (heart issues), which is a key factor in long-term health ^[16]. Your doctor may recommend a Cardiac MRI or an echocardiogram to ensure your heart is protected, even if you do not have chest pain ^[17]^[12]. By identifying the disease and beginning targeted treatments, the goal is to move the disease into remission and prevent further damage to your organs ^[7]^[18].

In this guide

6 chapters

The Clinical Phases of EGPA: A Roadmap for Patients

Learn the 3 clinical phases of Eosinophilic Granulomatosis with Polyangiitis (EGPA). Understand the symptoms of the allergic, eosinophilic & vasculitic stages.

The Biology of EGPA: Eosinophils, ANCA, and Look-Alikes

Learn the biology behind EGPA. Understand how eosinophils and ANCA status affect your symptoms and how doctors rule out look-alike conditions like GPA and HES.

Getting Diagnosed: The Tools and Criteria for EGPA

Learn how doctors diagnose Eosinophilic Granulomatosis with Polyangiitis (EGPA). Understand the role of AEC blood tests, ANCA testing, and tissue biopsies.

Standard of Care: Treating EGPA with Precision

Learn about EGPA (eosinophilic granulomatosis with polyangiitis) treatment options. Understand steroids, mepolizumab, rituximab, and managing side effects.

Predicting Your Path: The Five-Factor Score (FFS)

Learn how doctors use the Five-Factor Score (FFS) to determine Eosinophilic Granulomatosis with Polyangiitis (EGPA) severity and guide treatment decisions.

Building Your Care Team and Living Well with EGPA

Learn how to live well with EGPA. Discover how to build a multidisciplinary care team, manage the steroid burden, and monitor for relapse in survivorship.

Common questions in this guide

What are the three phases of EGPA?

EGPA typically progresses through an allergic phase with severe asthma, an eosinophilic phase with high white blood cell counts, and a vasculitic phase involving blood vessel inflammation. These phases do not always happen in a straight line and can overlap.

Why does getting an EGPA diagnosis take so long?

Early symptoms of EGPA, like asthma and chronic sinus issues, are very common in the general population. It usually isn't until more severe systemic symptoms appear that doctors suspect a rare disease and perform specialized blood tests and biopsies.

What is the long-term prognosis for someone with EGPA?

With modern targeted treatments, the long-term outlook for EGPA is excellent. Most patients can expect to live long, full lives, especially if the disease is properly managed to prevent further organ damage.

Why do I need a cardiac MRI if I have EGPA?

Checking for heart involvement is a critical part of early EGPA care because it strongly impacts your overall health. A cardiac MRI or echocardiogram helps doctors ensure your heart is protected, even if you are not experiencing chest pain.

What happens during the vasculitic phase of EGPA?

The vasculitic phase is the most serious stage of the disease, occurring when the blood vessels themselves become inflamed. Common signs include new skin rashes and severe nerve numbness or pain, a condition known as mononeuritis multiplex.

Curated prompts to bring to your next appointment.

1.Based on my history of asthma and current symptoms, what specific tests are needed to confirm or rule out EGPA?
2.What is my current absolute eosinophil count (AEC), and what does that tell us about my disease phase?
3.Have you checked my ANCA status, and how does that impact my diagnosis?
4.Should I have a cardiac MRI or echocardiogram now to check for heart involvement?
5.What specific red flags should I watch for that might indicate I am moving from the eosinophilic phase to the vasculitic phase?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (18)

1
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
Grayson PC, Ponte C, Suppiah R, et al.
Annals of the rheumatic diseases 2022; (81(3)):309-314 doi:10.1136/annrheumdis-2021-221794.
PMID: 35110334
2
When inflammation is not just inflammation-A review of systemic diseases of the nose and sinuses part 2: Granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Cler SJ, Ogden MA, Farrell NF, et al.
American journal of otolaryngology 2024; (45(3)):104207 doi:10.1016/j.amjoto.2023.104207.
PMID: 38176206
3
The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.
Berti A, Cornec D, Crowson CS, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(12)):2338-2350 doi:10.1002/art.40313.
PMID: 28881446
4
Incidence, Prevalence, and Mortality of Eosinophilic Granulomatosis With Polyangiitis in Korea: A Nationwide Population-Based Study.
Lee JH, Hong SH, Yu I, et al.
Allergy, asthma & immunology research 2024; (16(2)):168-178 doi:10.4168/aair.2024.16.2.168.
PMID: 38528384
5
Genetic and Non-Genetic Contributions to Eosinophilic Granulomatosis with Polyangiitis: Current Knowledge and Future Perspectives.
Treccani M, Veschetti L, Patuzzo C, et al.
Current issues in molecular biology 2024; (46(7)):7516-7529 doi:10.3390/cimb46070446.
PMID: 39057087
6
[A Rare Cause of a Eosinophilic Lung Disease].
Stolpe C, Tannapfel A
Pneumologie (Stuttgart, Germany) 2021; (75(3)):221-225 doi:10.1055/a-1220-7149.
PMID: 32927489
7
Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan.
Yamashita Y, Masumoto N, Takaoka S, et al.
Scientific reports 2026; (16(1)).
PMID: 41723230
8
The First Case of Eosinophilic Granulomatosis with Polyangiitis Simultaneously Demonstrating Various Clinical Manifestations with Retroperitoneal Fibrosis and Membranous Nephropathy.
Kondo I, Arai Y, Sakamoto E, et al.
Internal medicine (Tokyo, Japan) 2021; (60(12)):1963-1969 doi:10.2169/internalmedicine.6399-20.
PMID: 33518573
9
Hypertrophic Pachymeningitis, Associated with Eosinophilic Granulomatosis with Polyangiitis, and ANCA-Negative Serology.
Martínez-Piña DA, Calderón-Garcidueñas AL, Gama-Lizárraga E, et al.
European journal of case reports in internal medicine 2024; (11(7)):004595 doi:10.12890/2024_004595.
PMID: 38984173
10
[Clinical analysis of 43 patients with eosinophilic granulomatosis with polyangiitis].
Li J, Zhang L, Zhao W, et al.
Zhonghua yi xue za zhi 2016; (96(10)):787-91 doi:10.3760/cma.j.issn.0376-2491.2016.10.008.
PMID: 27055639
11
Clinical and Serological Features of Eosinophilic and Vasculitic Phases of Eosinophilic Granulomatosis with Poliangiitis: a Case Series of 15 Patients.
Yılmaz İ, Tutar N, Şimşek ZÖ, et al.
Turkish thoracic journal 2017; (18(3)):72-77 doi:10.5152/TurkThoracJ.2017.16040.
PMID: 29404165
12
Initial Hemorrhagic Pericardial Effusion Evolving Into Perimyocarditis: An Atypical Early Presentation of Eosinophilic Granulomatosis With Polyangiitis.
Almatrafi SA, Quqandi SM, Ismail SJ, Alghamdi KA
Cureus 2025; (17(7)):e88155 doi:10.7759/cureus.88155.
PMID: 40821336
13
Otologic Manifestations of Eosinophilic Granulomatosis With Polyangiitis: A Systematic Review.
Ashman PE, Chen T, Barinsky GL, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2021; (42(4)):e380-e387 doi:10.1097/MAO.0000000000003024.
PMID: 33534386
14
Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.
Shum M, Gewurz-Singer O, Silver J, Akuthota P
Frontiers in medicine 2025; (12()):1568770 doi:10.3389/fmed.2025.1568770.
PMID: 40630493
15
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.
Grayson PC, Ponte C, Suppiah R, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(3)):386-392 doi:10.1002/art.41982.
PMID: 35106968
16
Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments.
Segreti A, Mastroberardino S, Frau L, et al.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2025; (95(2)) doi:10.4081/monaldi.2024.2882.
PMID: 38700128
17
Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis.
Srikantharajah M, Gopalan D, Wilson-Morkeh H, et al.
Current cardiology reports 2025; (27(1)):109.
PMID: 40632386
18
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.
Ishii T, Kunishige H, Kobayashi T, et al.
Modern rheumatology 2025; (35(3)):505-515 doi:10.1093/mr/roae100.
PMID: 39508562

This page provides educational information about EGPA diagnosis and disease phases. It is for informational purposes only and does not replace professional medical advice from your rheumatologist or care team.

Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents